Negative Prognostic Impact of Splenic Vein Involvement in Resectable Pancreatic Body or Tail Cancer

Patients with resectable pancreatic body or tail cancer who have splenic vein (SPV) involvement, particularly radiological SPV encasement, experience significantly worse overall survival (OS) and recurrence-free survival (RFS). Independent poor prognostic factors include higher pre-operative carcinoembryonic antigen levels, larger tumor size, pathological SPV invasion, and non-completion of adjuvant therapy. Multidetector-row computed tomography shows relatively high accuracy in detecting pathological SPV invasion. Neoadjuvant therapy’s prognostic impact remains inconclusive. Innovative treatments and effective neoadjuvant therapy regimens are necessary for patients with SPV involvement.